Table 3 Summary of types of MEAs implemented in select countries
Country | MEA used | Medicines reimbursed |
|---|---|---|
Australia | The risk-sharing arrangement is captured through a legal deed of agreement (‘deed’) that is negotiated between the sponsor and the government. Some financial risk share arrangements can be class deeds where sponsors share the risk based on market share | A financial risk share was mentioned for 24 medicines in the most recent public summary documents |
England | NHS and manufacturers have an agreement and one of the functions of CDF is managed access fund providing conditional funding for cancer medicines where uncertainty is addressed through data collection. Dominantly financial MEAs in form of discounts are used, but outcome-based MEA is also performed | England has approved 42 medicines since the introduction of the CDF |
South Korea | Four types of MEAs: (i) coverage with additional evidence, (ii) expenditure cap refund, (iii) utilisation cap per patient and (iv) refund/expenditure cap | As of 2019, 39 medicines had been reimbursed under RSA |